- Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug<figure><div><img src="https://imgproxy.divecdn.com/8hRa8ccyqK4EhEh4oXaIz1XS7XE4MZBhJhutfBJVSSU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNzUyMzcxMjg5LmpwZ…BioPharma Dive · 2d ago↗ source
- Arrowhead’s gene silencer competitive with Ionis’ in triglyceride diseaseArrowhead Pharmaceuticals’ lipid-lowering drug has hit in two late-stage trials that could expand its use into a much wider population. Data shared Wednesday showed that Arrowhead’s gene silencer…Endpoints · 2d ago↗ source
- Summit and Akeso sharpen case for ivonescimab with new Western dataSummit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…